Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wee1 Inhibitor II is a potent, cell-permeable, and highly selective small molecule inhibitor of the Wee1 kinase, a critical regulator of the G2/M cell cycle checkpoint. By inhibiting Wee1, the compound prevents the inhibitory phosphorylation of Cdc2 (CDK1) at Tyr15, which promotes premature entry into mitosis and can lead to mitotic catastrophe in DNA-damaged cells. While primarily utilized as a research tool in oncology to study cell cycle arrest and DNA damage repair mechanisms, recent neurobiology research has identified its role in modulating the Nav1.2 channelosome. Specifically, Wee1 Inhibitor II has been shown to disrupt the interaction between fibroblast growth factor 14 (FGF14) and the voltage-gated sodium channel Nav1.2, thereby influencing neuronal excitability and firing properties. It is widely used in vitro and in cell-based assays to interrogate Wee1-mediated signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wee1 inhibitor ii.